25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

APLS (Apellis) Stock Analysis
Buy, Hold or Sell?

Let's analyze Apellis together

I guess you are interested in Apellis Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Apellis’s Financial Insights
  • 📈 Technical Analysis (TA) – Apellis’s Price Targets

I'm going to help you getting a better view of Apellis Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Apellis Pharmaceuticals Inc

I send you an email if I find something interesting about Apellis Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Apellis (30 sec.)










1.2. What can you expect buying and holding a share of Apellis? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
7.5%

What is your share worth?

Current worth
$1.31
Expected worth in 1 year
$0.49
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-0.82
Return On Investment
-4.2%

For what price can you sell your share?

Current Price per Share
$19.21
Expected price per share
$16.10 - $25.76
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Apellis (5 min.)




Live pricePrice per Share (EOD)
$19.21
Intrinsic Value Per Share
$-28.26 - $9.43
Total Value Per Share
$-26.95 - $10.74

2.2. Growth of Apellis (5 min.)




Is Apellis growing?

Current yearPrevious yearGrowGrow %
How rich?$164.2m$259.7m-$36.1m-16.2%

How much money is Apellis making?

Current yearPrevious yearGrowGrow %
Making money-$55.9m-$104.3m$48.3m86.5%
Net Profit Margin-30.1%-88.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Apellis (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#268 / 873

Most Revenue
#59 / 873

Most Profit
#792 / 873

Most Efficient
#451 / 873
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Apellis?

Welcome investor! Apellis's management wants to use your money to grow the business. In return you get a share of Apellis.

First you should know what it really means to hold a share of Apellis. And how you can make/lose money.

Speculation

The Price per Share of Apellis is $19.21. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Apellis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Apellis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.31. Based on the TTM, the Book Value Change Per Share is $-0.20 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.29 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Apellis.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.73-3.8%-0.44-2.3%-0.83-4.3%-0.88-4.6%-0.95-5.0%-0.63-3.3%
Usd Book Value Change Per Share-0.51-2.7%-0.20-1.1%-0.29-1.5%-0.20-1.0%-0.04-0.2%0.030.2%
Usd Dividend Per Share0.000.0%0.000.0%0.010.0%0.010.1%0.010.0%0.000.0%
Usd Total Gains Per Share-0.51-2.7%-0.20-1.1%-0.28-1.5%-0.18-1.0%-0.03-0.2%0.030.2%
Usd Price Per Share21.87-30.25-61.95-50.00-47.86-29.51-
Price to Earnings Ratio-7.45--20.70--20.25--17.13--12.08--9.61-
Price-to-Total Gains Ratio-42.73--673.93--80.87--283.42--174.52--129.44-
Price to Book Ratio16.74-16.95-30.03-24.27-19.98-16.28-
Price-to-Total Gains Ratio-42.73--673.93--80.87--283.42--174.52--129.44-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share19.21
Number of shares52
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.20-0.04
Usd Total Gains Per Share-0.20-0.03
Gains per Quarter (52 shares)-10.60-1.55
Gains per Year (52 shares)-42.39-6.22
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-42-522-8-16
20-85-943-16-22
30-127-1365-24-28
40-170-1786-31-34
50-212-2208-39-40
60-254-26210-47-46
70-297-30411-55-52
80-339-34613-63-58
90-382-38815-71-64
100-424-43016-78-70

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%1.019.00.05.0%2.038.00.05.0%2.043.01.04.3%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%6.014.00.030.0%12.024.04.030.0%15.024.07.032.6%
Dividend per Share0.00.04.00.0%3.00.09.025.0%3.00.017.015.0%3.00.037.07.5%3.00.043.06.5%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%6.014.00.030.0%12.024.04.030.0%15.024.07.032.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Apellis Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.512-0.204-60%-0.289-43%-0.198-61%-0.038-93%0.030-1831%
Book Value Per Share--1.3071.779-27%2.066-37%2.093-38%1.676-22%1.218+7%
Current Ratio--4.0804.444-8%4.066+0%4.999-18%6.263-35%8.372-51%
Debt To Asset Ratio--0.7970.746+7%0.693+15%0.702+13%0.771+3%0.542+47%
Debt To Equity Ratio--3.9163.003+30%2.337+68%2.504+56%3.118+26%2.057+90%
Dividend Per Share----0%0.006-100%0.013-100%0.008-100%0.004-100%
Enterprise Value--2463989340.0003532125090.000-30%7643475240.000-68%6187200741.667-60%5969503674.000-59%4962275912.133-50%
Eps---0.734-0.445-39%-0.830+13%-0.883+20%-0.952+30%-0.625-15%
Ev To Ebitda Ratio---7.663-26.705+249%-21.829+185%-19.895+160%-14.030+83%-15.264+99%
Ev To Sales Ratio--3.6934.518-18%15.898-77%32.421-89%294.252-99%4737.543-100%
Free Cash Flow Per Share---0.425-0.017-96%-1.096+158%-0.756+78%-0.745+75%-0.480+13%
Free Cash Flow To Equity Per Share---0.4230.065-746%-0.874+107%-0.403-5%-0.113-73%0.080-628%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--9.429----------
Intrinsic Value_10Y_min---28.256----------
Intrinsic Value_1Y_max---1.508----------
Intrinsic Value_1Y_min---3.012----------
Intrinsic Value_3Y_max---2.662----------
Intrinsic Value_3Y_min---8.947----------
Intrinsic Value_5Y_max---1.562----------
Intrinsic Value_5Y_min---14.724----------
Market Cap2414351220.000-14%2748665340.0003801252090.000-28%7785371490.000-65%6283576325.000-56%6014763474.000-54%3708435933.000-26%
Net Profit Margin---0.553-0.301-46%-0.886+60%-2.856+416%-32.129+5711%-114.645+20634%
Operating Margin---0.485-0.242-50%-0.824+70%-2.700+457%-30.939+6284%-151.365+31133%
Operating Ratio--1.5001.253+20%1.862-19%3.637-59%29.742-95%115.723-99%
Pb Ratio14.702-14%16.73816.953-1%30.028-44%24.268-31%19.980-16%16.281+3%
Pe Ratio-6.545+12%-7.451-20.703+178%-20.254+172%-17.134+130%-12.075+62%-9.606+29%
Price Per Share19.210-14%21.87030.245-28%61.945-65%49.996-56%47.857-54%29.507-26%
Price To Free Cash Flow Ratio-11.299+12%-12.864-19.360+50%-14.785+15%-15.567+21%-12.593-2%-11.121-14%
Price To Total Gains Ratio-37.535+12%-42.732-673.928+1477%-80.869+89%-283.419+563%-174.519+308%-129.439+203%
Quick Ratio--3.3793.657-8%3.225+5%4.396-23%7.099-52%8.848-62%
Return On Assets---0.114-0.065-43%-0.124+9%-0.128+12%-0.148+30%-0.249+118%
Return On Equity---0.562-0.276-51%-0.415-26%-0.439-22%-0.564+0%-0.581+3%
Total Gains Per Share---0.512-0.204-60%-0.283-45%-0.185-64%-0.030-94%0.033-1629%
Usd Book Value--164216000.000223550750.000-27%259717750.000-37%263075250.000-38%210655050.000-22%153101571.275+7%
Usd Book Value Change Per Share---0.512-0.204-60%-0.289-43%-0.198-61%-0.038-93%0.030-1831%
Usd Book Value Per Share--1.3071.779-27%2.066-37%2.093-38%1.676-22%1.218+7%
Usd Dividend Per Share----0%0.006-100%0.013-100%0.008-100%0.004-100%
Usd Enterprise Value--2463989340.0003532125090.000-30%7643475240.000-68%6187200741.667-60%5969503674.000-59%4962275912.133-50%
Usd Eps---0.734-0.445-39%-0.830+13%-0.883+20%-0.952+30%-0.625-15%
Usd Free Cash Flow---53418000.000-2102750.000-96%-137726250.000+158%-95068166.667+78%-93690950.000+75%-60352857.000+13%
Usd Free Cash Flow Per Share---0.425-0.017-96%-1.096+158%-0.756+78%-0.745+75%-0.480+13%
Usd Free Cash Flow To Equity Per Share---0.4230.065-746%-0.874+107%-0.403-5%-0.113-73%0.080-628%
Usd Market Cap2414351220.000-14%2748665340.0003801252090.000-28%7785371490.000-65%6283576325.000-56%6014763474.000-54%3708435933.000-26%
Usd Price Per Share19.210-14%21.87030.245-28%61.945-65%49.996-56%47.857-54%29.507-26%
Usd Profit---92225000.000-55920000.000-39%-104318250.000+13%-110997333.333+20%-119665450.000+30%-77885725.000-16%
Usd Revenue--166797000.000193960000.000-14%131017500.000+27%117149750.000+42%86869350.000+92%43431702.100+284%
Usd Total Gains Per Share---0.512-0.204-60%-0.283-45%-0.185-64%-0.030-94%0.033-1629%
 EOD+3 -5MRQTTM+4 -33YOY+19 -203Y+15 -245Y+17 -2210Y+16 -23

3.3 Fundamental Score

Let's check the fundamental score of Apellis Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.545
Price to Book Ratio (EOD)Between0-114.702
Net Profit Margin (MRQ)Greater than0-0.553
Operating Margin (MRQ)Greater than0-0.485
Quick Ratio (MRQ)Greater than13.379
Current Ratio (MRQ)Greater than14.080
Debt to Asset Ratio (MRQ)Less than10.797
Debt to Equity Ratio (MRQ)Less than13.916
Return on Equity (MRQ)Greater than0.15-0.562
Return on Assets (MRQ)Greater than0.05-0.114
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Apellis Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.881
Ma 20Greater thanMa 5018.234
Ma 50Greater thanMa 10018.182
Ma 100Greater thanMa 20020.704
OpenGreater thanClose18.100
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Fundamental data was last updated by Penke on 2025-07-10 20:54:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Apellis earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Apellis to the Biotechnology industry mean.
  • A Net Profit Margin of -55.3% means that $-0.55 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Apellis Pharmaceuticals Inc:

  • The MRQ is -55.3%. The company is making a huge loss. -2
  • The TTM is -30.1%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-55.3%TTM-30.1%-25.2%
TTM-30.1%YOY-88.6%+58.5%
TTM-30.1%5Y-3,212.9%+3,182.8%
5Y-3,212.9%10Y-11,464.5%+8,251.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-55.3%-92.7%+37.4%
TTM-30.1%-140.3%+110.2%
YOY-88.6%-196.4%+107.8%
3Y-285.6%-248.5%-37.1%
5Y-3,212.9%-343.4%-2,869.5%
10Y-11,464.5%-496.2%-10,968.3%
4.3.1.2. Return on Assets

Shows how efficient Apellis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Apellis to the Biotechnology industry mean.
  • -11.4% Return on Assets means that Apellis generated $-0.11 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Apellis Pharmaceuticals Inc:

  • The MRQ is -11.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.4%TTM-6.5%-4.9%
TTM-6.5%YOY-12.4%+5.9%
TTM-6.5%5Y-14.8%+8.3%
5Y-14.8%10Y-24.9%+10.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.4%-11.6%+0.2%
TTM-6.5%-11.6%+5.1%
YOY-12.4%-11.4%-1.0%
3Y-12.8%-11.8%-1.0%
5Y-14.8%-12.0%-2.8%
10Y-24.9%-13.7%-11.2%
4.3.1.3. Return on Equity

Shows how efficient Apellis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Apellis to the Biotechnology industry mean.
  • -56.2% Return on Equity means Apellis generated $-0.56 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Apellis Pharmaceuticals Inc:

  • The MRQ is -56.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -27.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-56.2%TTM-27.6%-28.5%
TTM-27.6%YOY-41.5%+13.9%
TTM-27.6%5Y-56.4%+28.7%
5Y-56.4%10Y-58.1%+1.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-56.2%-13.6%-42.6%
TTM-27.6%-15.0%-12.6%
YOY-41.5%-14.5%-27.0%
3Y-43.9%-16.9%-27.0%
5Y-56.4%-17.5%-38.9%
10Y-58.1%-19.9%-38.2%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Apellis Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Apellis is operating .

  • Measures how much profit Apellis makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Apellis to the Biotechnology industry mean.
  • An Operating Margin of -48.5% means the company generated $-0.48  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Apellis Pharmaceuticals Inc:

  • The MRQ is -48.5%. The company is operating very inefficient. -2
  • The TTM is -24.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-48.5%TTM-24.2%-24.3%
TTM-24.2%YOY-82.4%+58.3%
TTM-24.2%5Y-3,093.9%+3,069.7%
5Y-3,093.9%10Y-15,136.5%+12,042.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-48.5%-229.2%+180.7%
TTM-24.2%-249.0%+224.8%
YOY-82.4%-208.5%+126.1%
3Y-270.0%-223.8%-46.2%
5Y-3,093.9%-346.1%-2,747.8%
10Y-15,136.5%-475.5%-14,661.0%
4.3.2.2. Operating Ratio

Measures how efficient Apellis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.50 means that the operating costs are $1.50 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Apellis Pharmaceuticals Inc:

  • The MRQ is 1.500. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.253. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.500TTM1.253+0.247
TTM1.253YOY1.862-0.609
TTM1.2535Y29.742-28.490
5Y29.74210Y115.723-85.981
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5002.110-0.610
TTM1.2532.684-1.431
YOY1.8623.096-1.234
3Y3.6373.652-0.015
5Y29.7424.745+24.997
10Y115.7236.614+109.109
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Apellis Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Apellis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 4.08 means the company has $4.08 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Apellis Pharmaceuticals Inc:

  • The MRQ is 4.080. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.444. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.080TTM4.444-0.364
TTM4.444YOY4.066+0.378
TTM4.4445Y6.263-1.819
5Y6.26310Y8.372-2.108
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.0803.661+0.419
TTM4.4443.846+0.598
YOY4.0664.140-0.074
3Y4.9994.688+0.311
5Y6.2635.746+0.517
10Y8.3726.147+2.225
4.4.3.2. Quick Ratio

Measures if Apellis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Apellis to the Biotechnology industry mean.
  • A Quick Ratio of 3.38 means the company can pay off $3.38 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Apellis Pharmaceuticals Inc:

  • The MRQ is 3.379. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.657. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.379TTM3.657-0.278
TTM3.657YOY3.225+0.432
TTM3.6575Y7.099-3.442
5Y7.09910Y8.848-1.749
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3792.826+0.553
TTM3.6573.182+0.475
YOY3.2253.786-0.561
3Y4.3964.311+0.085
5Y7.0995.703+1.396
10Y8.8486.454+2.394
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Apellis Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Apellis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Apellis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.80 means that Apellis assets are financed with 79.7% credit (debt) and the remaining percentage (100% - 79.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Apellis Pharmaceuticals Inc:

  • The MRQ is 0.797. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.746. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.797TTM0.746+0.051
TTM0.746YOY0.693+0.053
TTM0.7465Y0.771-0.025
5Y0.77110Y0.542+0.229
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7970.329+0.468
TTM0.7460.349+0.397
YOY0.6930.331+0.362
3Y0.7020.340+0.362
5Y0.7710.349+0.422
10Y0.5420.379+0.163
4.5.4.2. Debt to Equity Ratio

Measures if Apellis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Apellis to the Biotechnology industry mean.
  • A Debt to Equity ratio of 391.6% means that company has $3.92 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Apellis Pharmaceuticals Inc:

  • The MRQ is 3.916. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.003. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ3.916TTM3.003+0.913
TTM3.003YOY2.337+0.667
TTM3.0035Y3.118-0.114
5Y3.11810Y2.057+1.060
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.9160.379+3.537
TTM3.0030.437+2.566
YOY2.3370.414+1.923
3Y2.5040.450+2.054
5Y3.1180.464+2.654
10Y2.0570.515+1.542
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Apellis generates.

  • Above 15 is considered overpriced but always compare Apellis to the Biotechnology industry mean.
  • A PE ratio of -7.45 means the investor is paying $-7.45 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Apellis Pharmaceuticals Inc:

  • The EOD is -6.545. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.451. Based on the earnings, the company is expensive. -2
  • The TTM is -20.703. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.545MRQ-7.451+0.906
MRQ-7.451TTM-20.703+13.252
TTM-20.703YOY-20.254-0.449
TTM-20.7035Y-12.075-8.628
5Y-12.07510Y-9.606-2.470
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.545-2.304-4.241
MRQ-7.451-2.080-5.371
TTM-20.703-2.564-18.139
YOY-20.254-3.764-16.490
3Y-17.134-3.773-13.361
5Y-12.075-6.193-5.882
10Y-9.606-6.833-2.773
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Apellis Pharmaceuticals Inc:

  • The EOD is -11.299. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -12.864. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -19.360. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.299MRQ-12.864+1.565
MRQ-12.864TTM-19.360+6.496
TTM-19.360YOY-14.785-4.575
TTM-19.3605Y-12.593-6.766
5Y-12.59310Y-11.121-1.472
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.299-3.132-8.167
MRQ-12.864-2.705-10.159
TTM-19.360-3.666-15.694
YOY-14.785-4.405-10.380
3Y-15.567-5.059-10.508
5Y-12.593-8.477-4.116
10Y-11.121-9.304-1.817
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Apellis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 16.74 means the investor is paying $16.74 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Apellis Pharmaceuticals Inc:

  • The EOD is 14.702. Based on the equity, the company is expensive. -2
  • The MRQ is 16.738. Based on the equity, the company is expensive. -2
  • The TTM is 16.953. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD14.702MRQ16.738-2.036
MRQ16.738TTM16.953-0.215
TTM16.953YOY30.028-13.075
TTM16.9535Y19.980-3.027
5Y19.98010Y16.281+3.699
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD14.7021.953+12.749
MRQ16.7381.843+14.895
TTM16.9532.112+14.841
YOY30.0282.441+27.587
3Y24.2682.494+21.774
5Y19.9803.661+16.319
10Y16.2814.311+11.970
4.6.2. Total Gains per Share

2.4. Latest News of Apellis Pharmaceuticals Inc

Does Apellis Pharmaceuticals Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Apellis Pharmaceuticals Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-07-10
14:26
Apellis stock holds Outperform rating at William Blair amid Izervay competitionRead
2025-07-06
10:15
Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold RatingRead
2025-07-01
18:51
Apellis stock maintains Outperform rating at William Blair on royalty dealRead
2025-06-29
08:22
Biotech Stocks Facing FDA Decision In July 2025Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Apellis Pharmaceuticals Inc.

4.8.1. Institutions holding Apellis Pharmaceuticals Inc

Institutions are holding 104.51% of the shares of Apellis Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Wellington Management Company LLP9.78920.0518123032525024034.2573
2025-03-31venBio Select Advisor LLC9.72474.17231222222200
2025-03-31EcoR1 Capital, LLC9.46515.43051189580849650.0418
2025-03-31Vanguard Group Inc8.06030.00410130356843310.8394
2025-03-31Morgan Stanley - Brokerage Accounts7.65910.01519626123-1104-0.0115
2025-03-31BlackRock Inc5.03620.00296329598-148391-2.2907
2025-03-31Deep Track Capital, LP3.97833.5409500000072507916.9612
2025-03-31AQR Capital Management LLC3.24420.091940774192220977119.6362
2025-03-31State Street Corp3.1360.00363941405-583750-12.9001
2025-03-31UBS Group AG2.60350.0132327219468545526.4988
2025-03-31Bank of America Corp2.49150.00553131436145122386.3714
2025-03-31Siren, L.L.C.2.05153.18092578396-237862-8.446
2025-03-31Jennison Associates LLC1.97130.0382477531-282873-10.2475
2025-03-31Octagon Capital Advisors LP1.66618.86152094000-912980-30.362
2025-03-31Geode Capital Management, LLC1.55160.003419500461110946.0412
2025-03-31Deutsche Bank AG1.41350.01541776576-1801-0.1013
2025-03-31BRAIDWELL LP1.31471.27031652334-446532-21.2749
2025-03-31Suvretta Capital Management, LLC1.31011.33631646615853428107.5948
2025-03-31Polar Capital Holdings PLC1.25490.2101157717500
2025-03-31FMR Inc1.1960.00211503209-624456-29.3494
Total 78.917738.249799185695+3399206+3.4%

4.9.2. Funds holding Apellis Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Vanguard Health Care Inv7.38890.521492865738091599.5449
2025-05-31Vanguard Total Stock Mkt Idx Inv2.71660.0032341429533340.0977
2025-05-31Vanguard Small Cap Index2.11950.0303266386297850.3687
2025-05-31SPDR® S&P Biotech ETF1.64920.74792072771122640.5952
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr1.32210.02571661587118370.7175
2025-05-31Vanguard Small Cap Growth Index Inv1.16720.07021466940-12587-0.8507
2025-04-30Polar Capital Biotech S Inc1.13381.52841425000-75000-5
2025-04-30DWS Vermögensbildungsfonds I LD1.05030.15381320024-7-0.0005
2025-03-31Vanguard Explorer Inv0.840.11631055763692177.0161
2025-03-31Jennison Health Sciences Equity0.68081.2469855674-173362-16.847
2025-05-31PGIM Jennison Health Sciences Z0.54610.866768630100
2025-05-31iShares Russell Mid-Cap Growth ETF0.50.057662844100
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.49580.025662307539000.6299
2025-05-31iShares Biotechnology ETF0.48680.207561184300
2025-04-30Fidelity Extended Market Index0.47330.031759488022150.3737
2025-05-31Schwab US Small-Cap ETF™0.40580.0521510030-1369-0.2677
2025-05-31Columbia Small Cap Value I A0.35470.505244583013071041.4794
2025-04-30Fidelity Growth Compy Commingled Pl S0.34820.0106437584-161400-26.9456
2025-04-30Fidelity Growth Company Fund0.33560.0138421811-116900-21.6999
2025-05-31iShares Russell 1000 Growth ETF0.3130.006339344700
Total 24.32776.221230575731+511796+1.7%

5.3. Insider Transactions

Insiders are holding 13.768% of the shares of Apellis Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2025-06-16David O WatsonSELL500018.77
2025-03-17James George ChopasSELL18324.82
2025-03-05David O WatsonSELL556925.1
2025-02-11Mark Jeffrey DelongSELL36328.54
2025-01-29Cedric FrancoisSELL282429.52
2025-01-29David O WatsonSELL69529.52
2025-01-29Nur NicholsonSELL82529.52
2025-01-29Timothy Eugene SullivanSELL54629.52
2025-01-22Cedric FrancoisSELL1355130.43
2025-01-22David O WatsonSELL332330.43
2025-01-22James George ChopasSELL109630.43
2025-01-22Nur NicholsonSELL394830.43
2025-01-22Timothy Eugene SullivanSELL308830.43
2025-01-17Cedric FrancoisSELL600729.96
2025-01-17Timothy Eugene SullivanSELL173029.96
2025-01-17Nur NicholsonSELL214529.96
2025-01-17James George ChopasSELL71529.96
2025-01-17David O WatsonSELL220129.96
2025-01-13Cedric FrancoisSELL624728.7
2025-01-13David O WatsonSELL496528.7
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets807,285
Total Liabilities643,069
Total Stockholder Equity164,216
 As reported
Total Liabilities 643,069
Total Stockholder Equity+ 164,216
Total Assets = 807,285

Assets

Total Assets807,285
Total Current Assets727,718
Long-term Assets79,567
Total Current Assets
Cash And Cash Equivalents 358,393
Net Receivables 244,377
Inventory 82,468
Other Current Assets 42,480
Total Current Assets  (as reported)727,718
Total Current Assets  (calculated)727,718
+/-0
Long-term Assets
Property Plant Equipment 17,765
Long-term Assets Other 61,802
Long-term Assets  (as reported)79,567
Long-term Assets  (calculated)79,567
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities178,377
Long-term Liabilities464,692
Total Stockholder Equity164,216
Total Current Liabilities
Short-term Debt 6,944
Accounts payable 55,287
Other Current Liabilities 116,146
Total Current Liabilities  (as reported)178,377
Total Current Liabilities  (calculated)178,377
+/-0
Long-term Liabilities
Long term Debt 453,422
Capital Lease Obligations Min Short Term Debt9,186
Long-term Liabilities Other 2,084
Long-term Liabilities  (as reported)464,692
Long-term Liabilities  (calculated)464,692
+/-0
Total Stockholder Equity
Common Stock12
Retained Earnings -3,127,591
Accumulated Other Comprehensive Income -3,054
Other Stockholders Equity 3,294,849
Total Stockholder Equity (as reported)164,216
Total Stockholder Equity (calculated)164,216
+/-0
Other
Capital Stock12
Cash and Short Term Investments 358,393
Common Stock Shares Outstanding 125,453
Liabilities and Stockholders Equity 807,285
Net Debt 111,159
Net Invested Capital 617,638
Net Working Capital 549,341
Property Plant and Equipment Gross 17,765
Short Long Term Debt Total 469,552



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-31
> Total Assets 
5,199
0
0
0
14,306
16,818
16,818
13,742
38,177
0
0
0
27,433
9,445
56,692
19,141
182,131
163,203
266,818
239,146
203,534
318,353
316,704
466,357
389,245
688,939
870,106
768,334
960,569
810,129
699,912
525,689
881,765
1,145,854
1,002,498
872,892
760,217
978,869
915,578
818,216
788,730
831,930
904,482
901,866
885,051
807,285
807,285885,051901,866904,482831,930788,730818,216915,578978,869760,217872,8921,002,4981,145,854881,765525,689699,912810,129960,569768,334870,106688,939389,245466,357316,704318,353203,534239,146266,818163,203182,13119,14156,6929,44527,43300038,17713,74216,81816,81814,3060005,199
   > Total Current Assets 
0
4,758
0
0
14,247
16,711
16,711
13,572
38,044
36,004
0
0
27,369
24,863
56,566
19,033
182,015
163,087
266,702
238,933
202,439
310,528
308,413
451,195
373,095
672,407
853,825
742,349
917,192
773,625
655,126
475,427
824,047
1,103,982
959,969
831,937
719,523
954,255
892,686
796,767
766,331
811,428
859,974
833,897
788,954
727,718
727,718788,954833,897859,974811,428766,331796,767892,686954,255719,523831,937959,9691,103,982824,047475,427655,126773,625917,192742,349853,825672,407373,095451,195308,413310,528202,439238,933266,702163,087182,01519,03356,56624,86327,3690036,00438,04413,57216,71116,71114,247004,7580
       Cash And Cash Equivalents 
4,758
-4,758
0
0
13,623
14,865
14,865
10,032
36,004
-36,004
0
0
24,863
-24,863
52,186
13,136
175,644
152,931
253,840
220,641
176,268
288,247
289,129
433,995
351,985
417,881
317,348
415,560
565,779
265,435
270,764
283,745
640,192
633,456
604,489
584,189
551,801
765,083
616,259
452,414
352,299
327,026
361,426
396,864
411,290
358,393
358,393411,290396,864361,426327,026352,299452,414616,259765,083551,801584,189604,489633,456640,192283,745270,764265,435565,779415,560317,348417,881351,985433,995289,129288,247176,268220,641253,840152,931175,64413,13652,186-24,86324,86300-36,00436,00410,03214,86514,86513,62300-4,7584,758
       Short-term Investments 
0
9,517
0
0
0
0
0
0
0
72,007
0
0
0
49,727
0
0
0
0
0
0
0
0
0
0
0
228,813
515,476
312,598
311,869
458,237
328,246
146,566
60,358
331,842
248,307
124,364
6,505
9,041
9,423
13,116
4,354
7,620
7,954
0
0
0
0007,9547,6204,35413,1169,4239,0416,505124,364248,307331,84260,358146,566328,246458,237311,869312,598515,476228,8130000000000049,72700072,00700000009,5170
       Net Receivables 
0
0
0
0
466
0
1,486
1,550
1,757
0
0
0
1,348
1,764
1,764
2,244
1,297
1,829
1,997
1,364
1,474
1,756
1,951
0
0
0
0
0
25,000
20,000
719
3,522
10,103
6,330
7,518
8,091
7,727
31,505
128,299
186,989
206,442
267,837
308,851
283,969
271,723
244,377
244,377271,723283,969308,851267,837206,442186,989128,29931,5057,7278,0917,5186,33010,1033,52271920,00025,000000001,9511,7561,4741,3641,9971,8291,2972,2441,7641,7641,3480001,7571,5501,48604660000
       Inventory 
0
0
0
0
137
0
311
1,931
0
0
0
0
0
0
0
0
0
6,293
8,860
15,482
0
0
0
0
0
0
0
0
0
0
3,731
1,677
16,286
32,850
48,451
59,753
85,714
85,484
103,216
98,545
146,362
161,283
152,772
121,058
81,404
82,468
82,46881,404121,058152,772161,283146,36298,545103,21685,48485,71459,75348,45132,85016,2861,6773,731000000000015,4828,8606,2930000000001,93131101370000
   > Long-term Assets 
0
-4,758
0
0
59
107
107
171
133
-36,004
0
0
65
-24,863
126
108
116
116
116
213
1,094
7,825
8,291
15,162
16,150
16,532
16,281
25,985
43,377
36,504
44,786
50,262
57,718
41,872
42,529
40,955
40,694
24,614
22,892
21,449
22,399
20,502
44,508
67,969
96,097
79,567
79,56796,09767,96944,50820,50222,39921,44922,89224,61440,69440,95542,52941,87257,71850,26244,78636,50443,37725,98516,28116,53216,15015,1628,2917,8251,094213116116116108126-24,8636500-36,0041331711071075900-4,7580
       Property Plant Equipment 
9
0
0
0
22
20
20
21
0
0
0
0
0
0
0
0
0
0
0
0
978
7,663
8,083
14,926
15,765
15,687
15,375
25,076
24,522
29,595
28,689
27,439
26,078
25,865
26,647
25,203
24,895
23,821
22,065
20,274
21,090
19,189
20,157
20,439
19,035
17,765
17,76519,03520,43920,15719,18921,09020,27422,06523,82124,89525,20326,64725,86526,07827,43928,68929,59524,52225,07615,37515,68715,76514,9268,0837,663978000000000000212020220009
       Other Assets 
0
0
0
0
37
0
0
150
133
0
0
0
64
126
127
108
116
116
116
213
1,094
162
208
237
385
845
906
909
18,855
6,909
16,097
22,823
31,640
16,007
15,882
15,752
15,799
0
0
0
0
0
0
0
0
0
00000000015,79915,75215,88216,00731,64022,82316,0976,90918,8559099068453852372081621,0942131161161161081271266400013315000370000
> Total Liabilities 
677
0
0
0
1,082
1,271
1,271
2,656
3,200
0
0
0
3,639
6,118
32,688
6,938
33,189
34,161
37,266
43,191
42,561
93,598
157,618
326,795
355,015
429,942
638,042
662,494
756,012
758,471
841,405
583,014
683,103
683,619
668,080
565,476
590,345
566,746
570,175
585,945
594,209
565,254
640,155
664,745
656,512
643,069
643,069656,512664,745640,155565,254594,209585,945570,175566,746590,345565,476668,080683,619683,103583,014841,405758,471756,012662,494638,042429,942355,015326,795157,61893,59842,56143,19137,26634,16133,1896,93832,6886,1183,6390003,2002,6561,2711,2711,082000677
   > Total Current Liabilities 
677
0
0
0
1,082
1,271
1,271
2,656
3,200
0
0
0
3,639
6,118
6,118
6,938
6,554
7,295
10,254
16,034
17,025
20,386
35,591
44,572
65,753
50,740
57,990
75,273
128,327
83,670
157,787
94,237
131,847
124,769
126,793
115,446
167,610
138,644
174,837
185,630
247,593
215,291
169,168
191,260
185,509
178,377
178,377185,509191,260169,168215,291247,593185,630174,837138,644167,610115,446126,793124,769131,84794,237157,78783,670128,32775,27357,99050,74065,75344,57235,59120,38617,02516,03410,2547,2956,5546,9386,1186,1183,6390003,2002,6561,2711,2711,082000677
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,390
26,616
26,761
0
1,667
1,128
1,550
2,304
2,609
2,732
2,664
3,438
3,685
3,902
4,035
4,072
4,115
4,560
5,312
5,423
5,625
5,828
5,852
5,739
6,441
6,257
12,428
13,584
6,753
6,944
6,9446,75313,58412,4286,2576,4415,7395,8525,8285,6255,4235,3124,5604,1154,0724,0353,9023,6853,4382,6642,7322,6092,3041,5501,1281,667026,76126,61626,3900000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,390
26,616
26,761
0
1,667
1,128
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000001,1281,667026,76126,61626,3900000000000000000
       Accounts payable 
354
0
0
0
752
830
830
1,268
2,477
0
0
0
2,547
2,604
2,604
4,001
3,663
4,585
5,133
5,469
10,255
11,916
13,812
11,837
8,361
3,078
9,927
11,069
8,477
4,158
5,339
4,984
16,909
12,273
16,220
14,099
37,342
31,494
27,500
18,192
37,516
26,788
38,270
42,730
38,572
55,287
55,28738,57242,73038,27026,78837,51618,19227,50031,49437,34214,09916,22012,27316,9094,9845,3394,1588,47711,0699,9273,0788,36111,83713,81211,91610,2555,4695,1334,5853,6634,0012,6042,6042,5470002,4771,268830830752000354
       Other Current Liabilities 
323
0
0
0
330
441
441
1,389
723
0
0
0
1,092
0
3,514
2,937
2,891
2,710
5,121
10,566
5,103
7,343
20,230
30,432
54,783
44,930
45,399
60,766
116,165
75,610
148,413
85,181
110,823
107,936
105,261
95,924
124,643
101,322
141,485
161,699
203,636
178,686
116,567
133,043
140,184
116,146
116,146140,184133,043116,567178,686203,636161,699141,485101,322124,64395,924105,261107,936110,82385,181148,41375,610116,16560,76645,39944,93054,78330,43220,2307,3435,10310,5665,1212,7102,8912,9373,51401,0920007231,389441441330000323
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
26,570
0
26,635
26,866
27,011
27,156
25,536
73,212
122,027
282,223
289,262
379,202
580,052
587,221
627,685
674,801
683,618
488,777
551,256
558,850
541,287
450,030
422,735
428,102
395,338
400,315
346,616
349,963
470,987
473,485
471,003
464,692
464,692471,003473,485470,987349,963346,616400,315395,338428,102422,735450,030541,287558,850551,256488,777683,618674,801627,685587,221580,052379,202289,262282,223122,02773,21225,53627,15627,01126,86626,635026,57000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
25,378
6,674
6,693
140,615
142,567
144,561
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000144,561142,567140,6156,6936,67425,37800000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
244
250
250
250
159
60,971
110,090
130,353
134,839
223,245
220,475
217,778
253,638
268,740
278,022
281,017
345,151
352,992
335,298
342,080
315,647
0
0
0
0
0
0
0
0
0
000000000315,647342,080335,298352,992345,151281,017278,022268,740253,638217,778220,475223,245134,839130,353110,09060,9711592502502502440000000000000000
> Total Stockholder Equity
4,522
4,523
0
0
13,225
15,547
15,547
11,086
34,977
34,977
0
0
23,794
23,794
24,003
12,203
148,943
129,042
229,552
195,955
160,973
224,755
159,086
139,562
34,230
258,997
232,064
105,840
204,557
51,658
-141,493
-57,325
198,662
462,235
334,418
307,416
169,872
412,123
345,403
232,271
194,521
266,676
264,327
237,121
228,539
164,216
164,216228,539237,121264,327266,676194,521232,271345,403412,123169,872307,416334,418462,235198,662-57,325-141,49351,658204,557105,840232,064258,99734,230139,562159,086224,755160,973195,955229,552129,042148,94312,20324,00323,79423,7940034,97734,97711,08615,54715,54713,225004,5234,522
   Common Stock
1
0
0
0
1
1
1
2
1
0
0
0
1
2
4
1
5
5
6
6
6
6
6
6
6
7
8
8
8
8
8
9
10
11
11
11
11
12
12
12
12
12
12
12
12
12
121212121212121212111111111098888876666666551421000121110001
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
-12,512
0
0
-22
0
-25
-28
0
-42,215
0
0
0
-68,261
-92,055
0
0
0
0
340
-123
-121
-122
-205
-154
1,010
329
-1,759
-117
-1,620
-1,829
-2,010
-2,090
-2,059
-3,194
-3,027
-875
-775
-796
-1,065
-3,542
-3,525
-3,362
-3,140
-3,308
-3,054
-3,054-3,308-3,140-3,362-3,525-3,542-1,065-796-775-875-3,027-3,194-2,059-2,090-2,010-1,829-1,620-117-1,7593291,010-154-205-122-121-1233400000-92,055-68,261000-42,2150-28-250-2200-12,5120
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
437,856
552,209
557,632
608,016
615,850
1,008,275
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000001,008,275615,850608,016557,632552,209437,85600000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
1,977
2,132
2,132
28,860
28,917
0
0
0
29,996
0
235,489
31,407
298,201
300,037
433,881
435,916
437,856
552,209
557,632
608,016
615,850
1,008,275
1,100,639
1,112,203
1,131,013
1,147,263
1,173,512
1,453,431
1,857,430
2,259,906
2,289,201
2,453,301
2,479,596
2,899,524
2,954,862
2,982,236
3,035,539
3,174,100
3,209,245
3,239,262
3,267,201
3,294,849
3,294,8493,267,2013,239,2623,209,2453,174,1003,035,5392,982,2362,954,8622,899,5242,479,5962,453,3012,289,2012,259,9061,857,4301,453,4311,173,5121,147,2631,131,0131,112,2031,100,6391,008,275615,850608,016557,632552,209437,856435,916433,881300,037298,20131,407235,489029,99600028,91728,8602,1322,1321,9770000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue781,367
Cost of Revenue-117,723
Gross Profit663,644663,644
 
Operating Income (+$)
Gross Profit663,644
Operating Expense-828,623
Operating Income-164,979-164,979
 
Operating Expense (+$)
Research Development327,570
Selling General Administrative501,053
Selling And Marketing Expenses0
Operating Expense828,623828,623
 
Net Interest Income (+$)
Interest Income12,773
Interest Expense-40,391
Other Finance Cost-0
Net Interest Income-27,618
 
Pretax Income (+$)
Operating Income-164,979
Net Interest Income-27,618
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-196,716-133,242
EBIT - interestExpense = -196,716
-196,716
-157,487
Interest Expense40,391
Earnings Before Interest and Taxes (EBIT)-156,325-156,325
Earnings Before Interest and Taxes (EBITDA)-154,528
 
After tax Income (+$)
Income Before Tax-196,716
Tax Provision-1,162
Net Income From Continuing Ops-197,878-197,878
Net Income-197,878
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses946,346
Total Other Income/Expenses Net-31,73727,618
 

Technical Analysis of Apellis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Apellis. The general trend of Apellis is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Apellis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Apellis Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Apellis Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 19.96 < 20.75 < 25.76.

The bearish price targets are: 17.15 > 16.61 > 16.10.

Know someone who trades $APLS? Share this with them.👇

Apellis Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Apellis Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Apellis Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Apellis Pharmaceuticals Inc. The current macd is -0.06578439.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Apellis price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Apellis. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Apellis price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Apellis Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartApellis Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Apellis Pharmaceuticals Inc. The current adx is 12.19.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Apellis shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Apellis Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Apellis Pharmaceuticals Inc. The current sar is 17.26.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Apellis Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Apellis Pharmaceuticals Inc. The current rsi is 57.88. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Apellis Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartApellis Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Apellis Pharmaceuticals Inc. The current phase is Overbought in bear market.

The long score for the Stochastic Oscillator is 6/6.
The longshort score for the Stochastic Oscillator is 6/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Apellis price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Apellis Pharmaceuticals Inc Daily Stochastic Oscillator ChartApellis Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Apellis Pharmaceuticals Inc. The current cci is 79.61.

Apellis Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartApellis Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Apellis Pharmaceuticals Inc. The current cmo is 25.65.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Apellis Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartApellis Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Apellis Pharmaceuticals Inc. The current willr is -0.96153846.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Apellis Pharmaceuticals Inc Daily Williams %R ChartApellis Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Apellis Pharmaceuticals Inc. The current atr is 0.84883794.

Apellis Pharmaceuticals Inc Daily Average True Range (ATR) ChartApellis Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Apellis Pharmaceuticals Inc. The current obv is -87,335,232.

Apellis Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartApellis Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Apellis Pharmaceuticals Inc. The current mfi is 50.78.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Apellis Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartApellis Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Apellis Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-24CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-01RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-11RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-22MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-05-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-05-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-30STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-07-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Apellis Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Apellis Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5057.881
Ma 20Greater thanMa 5018.234
Ma 50Greater thanMa 10018.182
Ma 100Greater thanMa 20020.704
OpenGreater thanClose18.100
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Apellis with someone you think should read this too:
  • Are you bullish or bearish on Apellis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Apellis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Apellis Pharmaceuticals Inc

I send you an email if I find something interesting about Apellis Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Apellis Pharmaceuticals Inc.

Receive notifications about Apellis Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.